US7601752B2 - Pyrrolidine derivatives - Google Patents
Pyrrolidine derivatives Download PDFInfo
- Publication number
- US7601752B2 US7601752B2 US11/593,821 US59382106A US7601752B2 US 7601752 B2 US7601752 B2 US 7601752B2 US 59382106 A US59382106 A US 59382106A US 7601752 B2 US7601752 B2 US 7601752B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- optionally substituted
- fluoro
- carbonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 0 C*C1CNC(*)C1 Chemical compound C*C1CNC(*)C1 0.000 description 35
- OZYVIPCQCPFYOW-CWQZNGJJSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C(=O)O Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C(=O)O OZYVIPCQCPFYOW-CWQZNGJJSA-N 0.000 description 2
- KVLSOCHGBGVMAL-LBAUFKAWSA-N O=C(N[C@@H]1CNC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@@H]1CNC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)C1)C1=CC=C(Cl)S1 KVLSOCHGBGVMAL-LBAUFKAWSA-N 0.000 description 2
- NSNBIODBSYJALS-LRDDRELGSA-N O=C(N[C@@H]1CN[C@H](C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)C1)C1=CC=C(Cl)S1.O=C(O)C(F)(F)F Chemical compound O=C(N[C@@H]1CN[C@H](C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)C1)C1=CC=C(Cl)S1.O=C(O)C(F)(F)F NSNBIODBSYJALS-LRDDRELGSA-N 0.000 description 2
- FZMYNXXCCCOLPN-NHYWBVRUSA-N O=C(N[C@@H]1CN[C@H](C(=O)NC2=CC=C(N3C=CN=CC3=O)C=C2F)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@@H]1CN[C@H](C(=O)NC2=CC=C(N3C=CN=CC3=O)C=C2F)C1)C1=CC=C(Cl)S1 FZMYNXXCCCOLPN-NHYWBVRUSA-N 0.000 description 2
- RIRGDWAFSJIFFP-ATNAJCNCSA-N O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)N(CCC(F)(F)F)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)N(CCC(F)(F)F)C1)C1=CC=C(Cl)S1 RIRGDWAFSJIFFP-ATNAJCNCSA-N 0.000 description 2
- KQIWQEMLNOGAMP-DIMJTDRSSA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N KQIWQEMLNOGAMP-DIMJTDRSSA-N 0.000 description 1
- ZVGDBDOYEFQUPT-ATNAJCNCSA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 ZVGDBDOYEFQUPT-ATNAJCNCSA-N 0.000 description 1
- UWHJDPJPZSUNQM-UCFFOFKASA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1C#N Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1C#N UWHJDPJPZSUNQM-UCFFOFKASA-N 0.000 description 1
- LIIUNZNTWYDJPS-HKUYNNGSSA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 LIIUNZNTWYDJPS-HKUYNNGSSA-N 0.000 description 1
- JYLSHGDHRBNWEU-KXBFYZLASA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F JYLSHGDHRBNWEU-KXBFYZLASA-N 0.000 description 1
- ALVKQASXDZPNOU-KSSFIOAISA-N CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F Chemical compound CC(C)(C)OC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F ALVKQASXDZPNOU-KSSFIOAISA-N 0.000 description 1
- QQCCZTLXHTYVAW-UWJYYQICSA-N CC(C)N1CCN(C2=CC=C(NC(=O)[C@@H]3C[C@H](NC(=O)C4=CC=C(Cl)S4)CN3C(C)C)C(F)=C2)C(=O)C1 Chemical compound CC(C)N1CCN(C2=CC=C(NC(=O)[C@@H]3C[C@H](NC(=O)C4=CC=C(Cl)S4)CN3C(C)C)C(F)=C2)C(=O)C1 QQCCZTLXHTYVAW-UWJYYQICSA-N 0.000 description 1
- RTRLUNQXWSGSOK-KXBFYZLASA-N CC(C)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound CC(C)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F RTRLUNQXWSGSOK-KXBFYZLASA-N 0.000 description 1
- KFNJMLOBMUUMRW-LROBGIAVSA-N CCOC(=O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound CCOC(=O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 KFNJMLOBMUUMRW-LROBGIAVSA-N 0.000 description 1
- LLEFVVKEXWTWBM-JXFKEZNVSA-N CCOC(=O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound CCOC(=O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F LLEFVVKEXWTWBM-JXFKEZNVSA-N 0.000 description 1
- QHJSHIZBGGVNBW-FUKCDUGKSA-N CCOC(=O)CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound CCOC(=O)CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F QHJSHIZBGGVNBW-FUKCDUGKSA-N 0.000 description 1
- RTQRPDOOZBRGHU-KSSFIOAISA-N CCOC(=O)CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F Chemical compound CCOC(=O)CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F RTQRPDOOZBRGHU-KSSFIOAISA-N 0.000 description 1
- AIHKYNJQUUGABL-KSSFIOAISA-N CCS(=O)(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound CCS(=O)(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F AIHKYNJQUUGABL-KSSFIOAISA-N 0.000 description 1
- MPLIXOMMRFEXIR-GUYCJALGSA-N CCS(=O)(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F Chemical compound CCS(=O)(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F MPLIXOMMRFEXIR-GUYCJALGSA-N 0.000 description 1
- PYIBGFOPZRIWAE-MYJWUSKBSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 PYIBGFOPZRIWAE-MYJWUSKBSA-N 0.000 description 1
- AIKFZSXQJFWQDL-BUSXIPJBSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N AIKFZSXQJFWQDL-BUSXIPJBSA-N 0.000 description 1
- POUFJKURJRUDML-NBLXOJGSSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1.O=CO Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1.O=CO POUFJKURJRUDML-NBLXOJGSSA-N 0.000 description 1
- AIKFZSXQJFWQDL-YJBOKZPZSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1C#N AIKFZSXQJFWQDL-YJBOKZPZSA-N 0.000 description 1
- WDUBQDNYLNRIES-HOCLYGCPSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 WDUBQDNYLNRIES-HOCLYGCPSA-N 0.000 description 1
- QZRLINAUSPSIRJ-YOEHRIQHSA-N CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1C#N Chemical compound CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1C#N QZRLINAUSPSIRJ-YOEHRIQHSA-N 0.000 description 1
- HVLUKMAXBSGCPI-MYJWUSKBSA-N COC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound COC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 HVLUKMAXBSGCPI-MYJWUSKBSA-N 0.000 description 1
- KKVYOKXZEXHWEA-GUYCJALGSA-N COC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F Chemical compound COC(=O)N1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F KKVYOKXZEXHWEA-GUYCJALGSA-N 0.000 description 1
- UETAYYNVKVPKKN-MBIQTGHCSA-N N#CC1=CC(N2C=CC=CC2=O)=CC=C1NC(=O)C1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1.O=C(O)C(F)(F)F Chemical compound N#CC1=CC(N2C=CC=CC2=O)=CC=C1NC(=O)C1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1.O=C(O)C(F)(F)F UETAYYNVKVPKKN-MBIQTGHCSA-N 0.000 description 1
- DFHPNARNTIAEJG-KNVGNIICSA-N N#CC1=CC(N2CCOCC2=O)=CC=C1NC(=O)C1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1.O=C(O)C(F)(F)F Chemical compound N#CC1=CC(N2CCOCC2=O)=CC=C1NC(=O)C1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1.O=C(O)C(F)(F)F DFHPNARNTIAEJG-KNVGNIICSA-N 0.000 description 1
- WFWPCZUKMAVJBO-ATNAJCNCSA-N N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 WFWPCZUKMAVJBO-ATNAJCNCSA-N 0.000 description 1
- SFIUIZNAJTVLNJ-MYJWUSKBSA-N N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 Chemical compound N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2CCOCC2=O)C=C1 SFIUIZNAJTVLNJ-MYJWUSKBSA-N 0.000 description 1
- YFRSLUGGZCIESH-GUYCJALGSA-N N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F Chemical compound N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F YFRSLUGGZCIESH-GUYCJALGSA-N 0.000 description 1
- VBMXSXXQANZSAD-WSZWBAFRSA-N N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(N)=O.O=C1C=CC=CN1C1=CC=CC(F)=C1 Chemical compound N#CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(N)=O.O=C1C=CC=CN1C1=CC=CC(F)=C1 VBMXSXXQANZSAD-WSZWBAFRSA-N 0.000 description 1
- OIZWZMYBVKWYKH-LEUCUCNGSA-N NC(=O)[C@@H]1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1CC(F)F.O=C1C=CC=CN1C1=CC=CC(F)=C1 Chemical compound NC(=O)[C@@H]1C[C@H](NC(=O)C2=CC=C(Cl)S2)CN1CC(F)F.O=C1C=CC=CN1C1=CC=CC(F)=C1 OIZWZMYBVKWYKH-LEUCUCNGSA-N 0.000 description 1
- UEBORFQLZHUERY-CFMCSPIPSA-N O=C(N[C@@H]1CNC(C(=O)NC2=CC=C(N3CCOCC3=O)C=C2)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@@H]1CNC(C(=O)NC2=CC=C(N3CCOCC3=O)C=C2)C1)C1=CC=C(Cl)S1 UEBORFQLZHUERY-CFMCSPIPSA-N 0.000 description 1
- WGCNMNVLDIXQEG-ATNAJCNCSA-N O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)N(CCO)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2)N(CCO)C1)C1=CC=C(Cl)S1 WGCNMNVLDIXQEG-ATNAJCNCSA-N 0.000 description 1
- HJHFVWHAQWFGIC-PIVQAISJSA-N O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)N(CCC(F)(F)F)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@H]1CC(C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)N(CCC(F)(F)F)C1)C1=CC=C(Cl)S1 HJHFVWHAQWFGIC-PIVQAISJSA-N 0.000 description 1
- FLJYCUNFCJBOJG-GUYCJALGSA-N O=C(N[C@H]1C[C@@H](C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)N(CC(F)(F)F)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@H]1C[C@@H](C(=O)NC2=CC=C(N3C=CC=CC3=O)C=C2F)N(CC(F)(F)F)C1)C1=CC=C(Cl)S1 FLJYCUNFCJBOJG-GUYCJALGSA-N 0.000 description 1
- XDGQOKVAYLLJQE-LRDDRELGSA-N O=C(N[C@H]1C[C@@H](C(=O)NC2=CC=C(N3C=CN=CC3=O)C=C2F)N(CC(F)F)C1)C1=CC=C(Cl)S1 Chemical compound O=C(N[C@H]1C[C@@H](C(=O)NC2=CC=C(N3C=CN=CC3=O)C=C2F)N(CC(F)F)C1)C1=CC=C(Cl)S1 XDGQOKVAYLLJQE-LRDDRELGSA-N 0.000 description 1
- UXYZLEBFBROVNA-ATNAJCNCSA-N O=C(O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1.[Li+] Chemical compound O=C(O)CCN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1.[Li+] UXYZLEBFBROVNA-ATNAJCNCSA-N 0.000 description 1
- ITJDGEANMGFPCT-CWQZNGJJSA-M O=C([O-])CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F.[Li+] Chemical compound O=C([O-])CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1F.[Li+] ITJDGEANMGFPCT-CWQZNGJJSA-M 0.000 description 1
- PQKORLHRAFPUQW-LRDDRELGSA-M O=C([O-])CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F.[Li+] Chemical compound O=C([O-])CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)C[C@H]1C(=O)NC1=CC=C(N2C=CN=CC2=O)C=C1F.[Li+] PQKORLHRAFPUQW-LRDDRELGSA-M 0.000 description 1
- LHFJAKQICLRGHZ-MYJWUSKBSA-N O=CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 Chemical compound O=CN1C[C@@H](NC(=O)C2=CC=C(Cl)S2)CC1C(=O)NC1=CC=C(N2C=CC=CC2=O)C=C1 LHFJAKQICLRGHZ-MYJWUSKBSA-N 0.000 description 1
- QZLSBOVWPHXCLT-UHFFFAOYSA-N OC(c([s]1)ccc1Cl)=O Chemical compound OC(c([s]1)ccc1Cl)=O QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- C 1-6 alkoxy alone or in combination with other groups, means the group R′—O—, wherein R′ is a C 1-6 alkyl.
- Example 10 was prepared in analogy to example 1, using 4-(4-amino-phenyl)-morpholin-3-one as amine component to yield (S)-4-[(5-chloro-thiophene-2-carbonyl)-amino]-2-[4-(3-oxo-morpholin-4-yl)-phenylcarbamoyl]-pyrrolidine-1-carboxylic acid tert-butyl ester as a white solid (mixture of epimers).
- MH + 549.1 (Cl-isotopes).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110818.1 | 2005-11-16 | ||
| EP05110818 | 2005-11-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20070112001A1 US20070112001A1 (en) | 2007-05-17 |
| US7601752B2 true US7601752B2 (en) | 2009-10-13 |
Family
ID=37618744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/593,821 Expired - Fee Related US7601752B2 (en) | 2005-11-16 | 2006-11-06 | Pyrrolidine derivatives |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7601752B2 (pt) |
| EP (1) | EP1951717A1 (pt) |
| JP (1) | JP2009515925A (pt) |
| KR (1) | KR101020440B1 (pt) |
| CN (1) | CN101309919A (pt) |
| AU (1) | AU2006314637A1 (pt) |
| BR (1) | BRPI0618610A2 (pt) |
| CA (1) | CA2629080A1 (pt) |
| WO (1) | WO2007057317A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
| AU2006301966A1 (en) * | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| EP2160392A2 (en) * | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| EP2155723A2 (en) * | 2007-05-10 | 2010-02-24 | F. Hoffmann-Roche AG | New solid forms of fxa inhibitors |
| EA201071034A1 (ru) * | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| IN2012DN02693A (pt) * | 2009-09-28 | 2015-09-04 | Intermune Inc | |
| CN104725374B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含双酰胺基和腈基苯结构的FXa抑制剂及其用途 |
| CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
| CN104860942B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含双酰胺基和硝基苯基结构的FXa抑制剂及其用途 |
| CN104557929B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
| CN104592227B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途 |
| CN104557930B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| WO2000078716A1 (en) | 1999-06-24 | 2000-12-28 | Toray Industries, Inc. | α1B-ADRENERGIC RECEPTOR ANTAGONISTS |
| WO2002022575A1 (en) | 2000-09-11 | 2002-03-21 | Genentech, Inc. | Amidine inhibitors of serine proteases |
| WO2002096873A1 (en) | 2001-05-31 | 2002-12-05 | Millennium Pharmaceuticals, Inc. | Isoindole and isoquinoline derivatives as inhibitors of factor xa |
| WO2003045912A1 (en) | 2001-11-29 | 2003-06-05 | Warner-Lambert Company Llc | Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| WO2003063797A2 (en) | 2002-02-01 | 2003-08-07 | Bristol-Myers Squibb Company | Cycloalkyl inhibitors of potassium channel function |
| WO2004058715A1 (ja) | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | ジアミン誘導体 |
| JP2004210716A (ja) | 2002-12-27 | 2004-07-29 | Dai Ichi Seiyaku Co Ltd | ジアミド誘導体 |
| WO2004082687A1 (en) | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
| WO2004087646A2 (de) | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen |
| WO2004087696A1 (de) | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen |
| WO2004110433A1 (de) | 2003-06-18 | 2004-12-23 | Merck Patent Gmbh | Pyrrolidin-1, 2- dicarbonsäure- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen |
| WO2005032472A2 (en) | 2003-10-01 | 2005-04-14 | Bristol-Myers Squibb Company | Pyrrolidine and piperidine derivatives as factor xa inhibitors |
| WO2006114401A2 (en) | 2005-04-27 | 2006-11-02 | F. Hoffmann-La Roche Ag | Novel cyclic amines |
| US7300929B2 (en) * | 1999-10-14 | 2007-11-27 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE324876T1 (de) * | 1999-10-14 | 2006-06-15 | Curis Inc | VERMITTLER VON ßHEDGEHOGß ÜBERMITTELNDEN BAHNEN, DAZUGEHÖRIGE ZUSAMMENETZUNGEN UND VERWENDUNGEN |
| JP4109890B2 (ja) * | 2001-04-19 | 2008-07-02 | 田辺三菱製薬株式会社 | 医薬組成物 |
| DE10329457A1 (de) * | 2003-04-03 | 2005-01-20 | Merck Patent Gmbh | Ethinylprolinderivate |
| WO2005040172A1 (ja) * | 2003-10-29 | 2005-05-06 | Kyowa Hakko Kogyo Co., Ltd. | 三環性プロリン誘導体 |
-
2006
- 2006-11-06 AU AU2006314637A patent/AU2006314637A1/en not_active Abandoned
- 2006-11-06 BR BRPI0618610-6A patent/BRPI0618610A2/pt not_active IP Right Cessation
- 2006-11-06 US US11/593,821 patent/US7601752B2/en not_active Expired - Fee Related
- 2006-11-06 EP EP06807756A patent/EP1951717A1/en not_active Withdrawn
- 2006-11-06 CN CNA2006800424500A patent/CN101309919A/zh active Pending
- 2006-11-06 KR KR1020087011614A patent/KR101020440B1/ko not_active Expired - Fee Related
- 2006-11-06 WO PCT/EP2006/068138 patent/WO2007057317A1/en not_active Ceased
- 2006-11-06 JP JP2008540572A patent/JP2009515925A/ja active Pending
- 2006-11-06 CA CA002629080A patent/CA2629080A1/en not_active Abandoned
Patent Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| WO2000078716A1 (en) | 1999-06-24 | 2000-12-28 | Toray Industries, Inc. | α1B-ADRENERGIC RECEPTOR ANTAGONISTS |
| US6642228B1 (en) | 1999-06-24 | 2003-11-04 | Toray Industries, Inc. | α1b-adrenergic receptor antagonists |
| US7300929B2 (en) * | 1999-10-14 | 2007-11-27 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2002022575A1 (en) | 2000-09-11 | 2002-03-21 | Genentech, Inc. | Amidine inhibitors of serine proteases |
| WO2002096873A1 (en) | 2001-05-31 | 2002-12-05 | Millennium Pharmaceuticals, Inc. | Isoindole and isoquinoline derivatives as inhibitors of factor xa |
| WO2003045912A1 (en) | 2001-11-29 | 2003-06-05 | Warner-Lambert Company Llc | Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| WO2003063797A2 (en) | 2002-02-01 | 2003-08-07 | Bristol-Myers Squibb Company | Cycloalkyl inhibitors of potassium channel function |
| US20060252837A1 (en) | 2002-12-25 | 2006-11-09 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| WO2004058715A1 (ja) | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | ジアミン誘導体 |
| JP2004210716A (ja) | 2002-12-27 | 2004-07-29 | Dai Ichi Seiyaku Co Ltd | ジアミド誘導体 |
| WO2004082687A1 (en) | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
| WO2004087696A1 (de) | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen |
| US20060183742A1 (en) | 2003-04-03 | 2006-08-17 | Werner Mederski | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses |
| US20060183739A1 (en) | 2003-04-03 | 2006-08-17 | Christos Tsaklakidis | Carbonyl compounds |
| WO2004087646A2 (de) | 2003-04-03 | 2004-10-14 | Merck Patent Gmbh | Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen |
| WO2004110433A1 (de) | 2003-06-18 | 2004-12-23 | Merck Patent Gmbh | Pyrrolidin-1, 2- dicarbonsäure- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen |
| WO2005032472A2 (en) | 2003-10-01 | 2005-04-14 | Bristol-Myers Squibb Company | Pyrrolidine and piperidine derivatives as factor xa inhibitors |
| WO2006114401A2 (en) | 2005-04-27 | 2006-11-02 | F. Hoffmann-La Roche Ag | Novel cyclic amines |
Non-Patent Citations (5)
| Title |
|---|
| Cheng et al., Biochem. Pharmacol., 22, pp. 3099-3108 (1973). |
| Eadie, G.S., J. Biol. Chem., 146, pp. 85-93 (1942). |
| Izawa et al., Tetrahedron, 48, pp. 1573-1580 (1992). |
| Lottenberg et al., Biochm. Biophys. Acta, 742, pp. 539-557 (1983). |
| Misumi et al., J. Am. Chem. Soc., 107, pp. 3343-3345 (1985). |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0618610A2 (pt) | 2011-09-06 |
| KR20080059448A (ko) | 2008-06-27 |
| EP1951717A1 (en) | 2008-08-06 |
| CN101309919A (zh) | 2008-11-19 |
| KR101020440B1 (ko) | 2011-03-08 |
| JP2009515925A (ja) | 2009-04-16 |
| WO2007057317A1 (en) | 2007-05-24 |
| CA2629080A1 (en) | 2007-05-24 |
| AU2006314637A1 (en) | 2007-05-24 |
| US20070112001A1 (en) | 2007-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678917B2 (en) | Factor Xa inhibitors | |
| US20070112012A1 (en) | Carbocyclic fused cyclic amines | |
| US7601752B2 (en) | Pyrrolidine derivatives | |
| US7417144B2 (en) | Factor Xa inhibitors | |
| US7718679B2 (en) | Heteroaryl carboxamides | |
| HK1117157A1 (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors | |
| HK1117157B (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY, SWITZERL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANSELM, LILLI;ZBINDEN, KATRIN GROEBKE;HAAP, WOLFGANG;AND OTHERS;REEL/FRAME:020001/0280;SIGNING DATES FROM 20061013 TO 20061023 Owner name: F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY,SWITZERLA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANSELM, LILLI;ZBINDEN, KATRIN GROEBKE;HAAP, WOLFGANG;AND OTHERS;SIGNING DATES FROM 20061013 TO 20061023;REEL/FRAME:020001/0280 Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:020001/0074 Effective date: 20061027 Owner name: HOFFMANN-LA ROCHE INC.,NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:020001/0074 Effective date: 20061027 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131013 |